Cardiovascular effects of anti-diabetic medications in type 2 diabetes mellitus (Q38068353)

28 August 2017

1 reference

title

Cardiovascular effects of anti-diabetic medications in type 2 diabetes mellitus (English)

1 reference

28 August 2017

1 reference

Samar Singh

1

1 reference

28 August 2017

Jyoti Bhat

series ordinal

2

1 reference

28 August 2017

Ping H Wang

series ordinal

3

1 reference

28 August 2017

1 January 2013

1 reference

Current cardiology reports

28 August 2017

1 reference

28 August 2017

15

1 reference

28 August 2017

1

1 reference

28 August 2017

327

1 reference

https://scigraph.springernature.com/pub.10.1007/s11886-012-0327-1

28 August 2017

0 references

cites work

Oral hypoglycaemic agents, insulin resistance and cardiovascular disease in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Effects of intensive glucose lowering in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

The cardioprotective effects of metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Cardiovascular outcomes in trials of oral diabetes medications: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Metformin use and mortality among patients with diabetes and atherothrombosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

The risk of heart failure in patients with type 2 diabetes treated with oral agent monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

The sulfonylurea controversy: more questions from the heart

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

The risk of overall mortality in patients with type 2 diabetes receiving glipizide, glyburide, or glimepiride monotherapy: a retrospective analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Ischemic preconditioning during coronary angioplasty is prevented by glibenclamide, a selective ATP-sensitive K+ channel blocker.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Impact of type of preadmission sulfonylureas on mortality and cardiovascular outcomes in diabetic patients with acute myocardial infarction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Medical significance of peroxisome proliferator-activated receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Management of hyperglycemia in type 2 diabetes: A consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

A meta-analysis of the effect of thiazolidinediones on blood pressure

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Are the effects of alpha-glucosidase inhibitors on cardiovascular events related to elevated levels of hydrogen gas in the gastrointestinal tract?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Post-meal glucose peaks at home associate with carotid intima-media thickness in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Glucose oscillations, more than constant high glucose, induce p53 activation and a metabolic memory in human endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Therapeutic potentials of acarbose as first-line drug in NIDDM insufficiently treated with diet alone

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

An alpha-glucosidase inhibitor, voglibose, reduces oxidative stress markers and soluble intercellular adhesion molecule 1 in obese type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

The role of incretins in glucose homeostasis and diabetes treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Incretin-based therapies in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Bariatric surgery versus conventional medical therapy for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Weight loss, glycemic control, and changes in cardiovascular biomarkers in patients with type 2 diabetes receiving incretin therapies or insulin in a large cohort database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Diabetes and cardiovascular disease: the potential benefit of incretin-based therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Cardiovascular benefits of GLP-1-based herapies in patients with diabetes mellitus type 2: effects on endothelial and vascular dysfunction beyond glycemic control

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Risk of cardiovascular disease events in patients with type 2 diabetes prescribed the glucagon-like peptide 1 (GLP-1) receptor agonist exenatide twice daily or other glucose-lowering therapies: a retrospective analysis of the LifeLink database

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11886-012-0327-1

Benefits and harms of antidiabetic agents in patients with diabetes and heart failure: systematic review

21 January 2018

1 reference

12 December 2020

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group

1 reference

12 December 2020

Epidemiology of hypertension and insulin resistance syndrome.

1 reference

12 December 2020

Increase in overall mortality risk in patients with type 2 diabetes receiving glipizide, glyburide or glimepiride monotherapy versus metformin: a retrospective analysis

1 reference

12 December 2020

Should We Use PPAR Agonists to Reduce Cardiovascular Risk?

1 reference

12 December 2020

Alpha-glucosidase inhibitors 2012 - cardiovascular considerations and trial evaluation

1 reference

12 December 2020

Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide

1 reference

12 December 2020

10.1007/S11886-012-0327-1

Identifiers

DOI

1 reference

Dimensions Publication ID

28 August 2017

0 references

1 reference